- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
All Names： Apalutamide，Erleada
Indications：1. Metastatic castration-sensitive prostate cancer (mCSPC); 2. Non-metastatic castration-resistant prostate cancer (nmCRPC)
Manufacturer：Everest Medicines, Bangladesh
Customs Clearance Procedure：If the customs requires the package for customs clearance, please pay the customs clearance fee according to the content of EMS SMS and customs regulations.
INDICATIONS AND USAGE（适应症）
ERLEADA is indicated for the treatment of patients with:
Metastatic castration-sensitive prostate cancer (mCSPC)
Non-metastatic castration-resistant prostate cancer (nmCRPC)
DOSAGE（服用剂量）
The recommended dose of ERLEADA is 240 mg (four 60 mg tablets) administered orally once daily. Swallow the tablets whole. ERLEADA can be taken with or without food.
Patients should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had a bilateral orchiectomy.
ADVERSE REACTIONS（不良反应）
Cerebrovascular and Ischemic Cardiovascular Events
Fractures
Falls
Seizure
For full information, please refer to:
https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/d1cda4f7-cb33-46ea-b9ac-431f6452b1a5/spl-doc?hl=Apalutamide
prostaxeninformation
No information yet!!!
